A multivalent Plasmodium falciparum circumsporozoite protein‐based nanoparticle malaria vaccine elicits a robust and durable antibody response against the junctional epitope and the major repeats

Abstract

Abstract Plasmodium falciparum (Pf) malaria continues to cause considerable morbidity and mortality worldwide. The circumsporozoite protein (CSP) is a particularly attractive candidate for designing vaccines that target sporozoites—the first vertebrate stage in a malaria infection. Current PfCSP‐based vaccines, however, do not include epitopes that have recently been shown to be the target of potent neutralizing antibodies. We report the design of a SpyCatcher‐mi3‐nanoparticle‐based vaccine presenting multiple copies of a chimeric PfCSP (cPfCSP) antigen that incorporates these important “T1/junctional” epitopes as well as a reduced number of (NANP)n repeats. cPfCSP‐SpyCatcher‐mi3 was immunogenic in mice eliciting high and durable IgG antibody levels as well as a balanced antibody response against the T1/junctional region and the (NANP)n repeats. Notably, the antibody concentration elicited by immunization was significantly greater than the reported protective threshold defined in a murine challenge model. Refocusing the immune response toward functionally relevant subdominant epitopes to induce a more balanced and durable immune response may enable the design of a more effective second generation PfCSP‐based vaccine.

Keywords

• circumsporozoite
• junctional epitope
• malaria
• Plasmodium falciparum
• vaccine